Hetero Launches Biosimilar 'Bevacizumab' for the Treatment of Metastatic Colorectal Cancer (mCRC) Under the Brand Name 'CizumabTM'
HYDERABAD, India, June 27, 2016 /PRNewswire/ --
Hetero, one of India's leading generic pharmaceutical companies, today announces the launch of Biosimilar 'Bevacizumab' in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name 'CizumabTM'
The product has been approved by Drug Controller General of India (DCGI) and has been recommended as a first-line treatment for mCRC. The product will be made available to patients in a single dose vial with two strengths, 100 mg and 400 mg. It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero.
Commenting on the launch of the product, Dr BPS Reddy, CMD, Hetero Group of Companies said, "It has been an exciting journey for us in Biologics. Hetero's Bevacizumab is the third product in our biologics portfolio, after Darbepoetin alfa and Rituximab. We believe CizumabTM will be a cost-effective treatment option to patients in India."
The product will be manufactured in the company's dedicated state-of-the-art biologics facility based in Hyderabad, India.
Hetero is one of India's leading generic pharmaceutical companies and is one of the world's largest producers of anti-retroviral drugs for the treatment of HIV/AIDS. With more than 20 years of expertise in the pharmaceutical industry, Hetero's strategic business areas include APIs, finished formulations and biosimilars. Hetero also offers custom pharmaceutical services to its partners around the world. The company is recognized for its strengths in Research & Development, manufacturing and commercialization of a wide range of products.
Hetero has more than 25 state-of-the-art manufacturing facilities strategically located worldwide. Majority of our facilities have been successfully audited and approved by various regulatory authorities like US-FDA, EU, TGA - Australia, MCC - South Africa and others. Our portfolio includes more than 200 products, encompassing major therapeutic categories such as HIV/AIDS, oncology, cardiovascular, neurology, hepatitis, etc.
Hetero has a strong global presence in over 120 countries and focuses on making affordable medicines accessible to patients worldwide.
Media Contact: A Jeyasingh Balakrishnan Corporate Communications Hetero Mobile: +91-9989626541/ +91-9833836185 Email: firstname.lastname@example.org